Who founded Sen-Jam Pharmaceutical?

Sen-Jam Pharmaceutical was founded by Jacqueline Iversen, James Iversen in 2017.

How much funding has Sen-Jam Pharmaceutical raised?

Sen-Jam Pharmaceutical has disclosed $480K raised across 2 of its 3 known rounds.

Where is Sen-Jam Pharmaceutical headquartered?

Sen-Jam Pharmaceutical is headquartered in Huntington, US.

Sen-Jam Pharmaceutical

Huntington, US · Founded 2017 · Delaware corporation · 12 employees on LinkedIn

Find your way into Sen-Jam Pharmaceutical

99 people in our graph share verified history with the Sen-Jam Pharmaceutical team — schools, employers, funds. One of them is your warm intro.

Doug Williamsunlockedknows Jacqueline Iversen · together at University at Buffalo Pharmacy and Pharmaceutical Sciences (overlapped)

×8knows the team · via Memorial Sloan Kettering Cancer Center

×3knows the team · via St. John's University

Sen-Jam is a computational drug discovery and development company developing a class of anti-inflammatory therapeutics based on combinations of already-approved small molecules (NSAIDs and antihistamines). Its pipeline targets conditions including alcohol hangover, viral and coronavirus infections, vaccine side effects, arthritis, and opioid dependence, tolerance, and withdrawal.

Biotech Healthtech Longevity

Founders & leadership

Sen-Jam Pharmaceutical was founded in 2017 by Jacqueline Iversen and James Iversen.

Jacqueline Iversen inCo-founder · Chief Clinical OfficerIversen holds a BS in Pharmacy from University of Buffalo and an MS in Clinical Pharmacy from St. John's University, and has published research in pharmacokinetics and clinical pain management. She is Chief Clinical Officer at Sen-Jam Pharmaceutical.

James IversenCo-founder

Funding

SEC filings, press & company announcements

$480K disclosed across 2 of 3 rounds · 2020–2023

Undisclosed amountSeries AOct 2022
Source ↗

▶$295KraisedJul 2024 · 6 investors · Pharmaceuticals

Rule 506(c)

Officers, directors & promoters on the filing

Jacqueline IversenExecutive Officer
James IversenDirector, Executive Officer

Offering amount: $10M
Amount sold: $295K
First sale: Apr 2023
Incorporated: Corporation, Delaware
Federal exemptions: 06c

Full filing on SEC EDGAR ↗

▶$185KraisedJun 2020 · 5 investors · Pharmaceuticals

Rule 506(c)

Officers, directors & promoters on the filing

James IversenExecutive Officer, Promoter

Offering amount: $3.2M
Amount sold: $185K
First sale: Jan 2020
Incorporated: Limited Liability Company, Delaware, 2017
Federal exemptions: 06c

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 2

by search overlap

Johnson & Johnson13 shared keywordsJohnson & Johnson develops prescription medicines and medical technology across areas including oncology, immunology, neuroscience, cardiopulmonary, cardiovascular, orthopaedics, surgery, and vision. Its two main businesses, Innovative Medicine and MedTech, focus on treating complex diseases through science-based drugs and less invasive, personalized medical devices.

Redica5 shared keywordsRedica offers an AI-enriched intelligence platform that unifies global regulatory, inspection, site, and post-market data to help companies manage risk and protect product quality. It serves quality, regulatory, and supply chain teams across industries including pharmaceutical, medtech, cosmetics, supplements, food, and financial services.

Companies competing with Sen-Jam Pharmaceutical for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

Sen-Jam Partners Strikes Deal with 5 Horizons Capital to Support Phase II Trial of SJP-001 for Inflammation, Metabolic Health | PharmExecpharmexec.com · Jun 2026

Sen-Jam Pharmaceutical on Wefunder 2025 - Kingscrowdkingscrowd.com · Jun 2025

Sen-Jam Pharmaceutical Secures Financial and Strategic Investment from 5 Horizons Capital to Advance SJP-001 Clinical Trial with Novotechprnewswire.com · Jan 2025

Sen-Jam Pharmaceutical on Dealmaker Securities 2023 - Kingscrowdkingscrowd.com · Apr 2023

Sen-Jam Pharmaceutical, the World's Most Resourceful Drug Innovator, Turns to Both Private and Institutional Investors to Secure Series A Financing to Further Advance Critical Therapeutics - BioSpacebiospace.com · Oct 2022

Sen-Jam Pharmaceutical - featured on investibuleinvestibule.co

Frequently asked questions

What does Sen-Jam Pharmaceutical do?: Sen-Jam is a computational drug discovery and development company developing a class of anti-inflammatory therapeutics based on combinations of already-approved small molecules (NSAIDs and antihistamines). Its pipeline targets conditions including alcohol hangover, viral and coronavirus infections, vaccine side effects, arthritis, and opioid dependence, tolerance, and withdrawal.
Who founded Sen-Jam Pharmaceutical?: Sen-Jam Pharmaceutical was founded by Jacqueline Iversen, James Iversen in 2017.
How much funding has Sen-Jam Pharmaceutical raised?: Sen-Jam Pharmaceutical has disclosed $480K raised across 2 of its 3 known rounds.
Where is Sen-Jam Pharmaceutical headquartered?: Sen-Jam Pharmaceutical is headquartered in Huntington, US.